MIBG imaging

Journal of Nuclear Cardiology

Volumn 9, Issue 1, 2002, Pages 75-94

  Patel, Amar D ^a   Iskandrian, Ami E ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 6 FLUORODOPA F 18; ADRENALIN; ADRENERGIC RECEPTOR; ANTHRACYCLINE DERIVATIVE; ANTIINFECTIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBON 11; CYANOPINDOLOL I 125; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; IODINE 123; IODINE 125; METARAMINOL; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PHENYLEPHRINE; PRACTOLOL; PRAZOSIN; QUINUCLIDINYL BENZILATE; RADIOPHARMACEUTICAL AGENT; SPIRONOLACTONE; TETROFOSMIN; TRACER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARRHYTHMOGENESIS; CARDIOMYOPATHY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DIABETES MELLITUS; DOG; DOSE RESPONSE; DRUG DISTRIBUTION; HEART INFARCTION; HEART INNERVATION; HEART MUSCLE BLOOD FLOW; HEART SCINTISCANNING; HUMAN; HUMAN TISSUE; ISCHEMIC HEART DISEASE; ISOTOPE LABELING; LONG QT SYNDROME; NONHUMAN; PARASYMPATHETIC INNERVATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPATHETIC INNERVATION;

EID: 0036185538     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1067/mnc.2002.121471     Document Type: Article

References (183)

1. Augmented alpha-adrenergic constriction of atherosclerotic human coronary arteries
2. Measuring acute changes in adrenergic nerve activity of the heart in the living animal
3. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man
4. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function
5. Myocardial imaging in man with I-123 meta-iodobenzylguanidine
6. Congenital myocardial sympathetic dysinnervation (CMSD)-a structural defect of idiopathic long QT syndrome
7. Heterogeneity of the human myocardial sympathetic innervation: In vivo demonstration by iodine 123-labeled meta-iodobenzylguanidine scintigraphy
8. Regional myocardial sympathetic dysinnervation in arrhythmogenic right ventricular cardiomyopathy
9. Metaiodobenzylguanidine imaging in diabetes mellitus: Assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia
10. Evaluation of cardiac sympathetic innervation with iodine-123-metaiodobenzylguanidine imaging in silent myocardial ischemia
11. Evaluation of QT interval length, QT dispersion and myocardial m-iodobenzylguanidine uptake in insulin-dependent diabetic patients with and without autonomic neuropathy
12. Direct evidence of impaired cardiac sympathetic innervation in essential hypertensive patients with left ventricular hypertrophy
13. 123I:metaiodobenzylguanidine left ventricular imaging
14. 123I MIBG uptake and increased clearance in various cardiac diseases
15. Age and gender differences in normal myocardial adrenergic neuronal function evaluated by iodine-123-MIBG imaging
16. Regional abnormality of iodine-123-MIBG in diabetic hearts
17. Use of iodine-123 metaiodobenzylguanidine scintigraphy to assess cardiac sympathetic denervation and the impact of hypertension in patients with non-insulin-dependent diabetes mellitus
18. 123I]metaiodobenzylguanidine scintigraphy: A 4-year prospective study in IDDM patients
19. Denervation supersensitivity of refractoriness in noninfarcted areas apical to transmural myocardial infarction
20. Influence of myocardial ischemia and infarction on autonomic innervation of heart
21. Scintigraphic and electrophysiological evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application
22. Scintigraphic detection of regional disruption of adrenergic neurons in the heart
23. Scintigraphic assessment of sympathetic innervation after transmural versus nontransmural myocardial infarction
24. 123I-metaiodobenzylguanidine
25. Serial assessment of denervated but viable myocardium following acute myocardial infarction in dogs using iodine-123 metaiodobenzylguanidine and thallium-201 chloride myocardial single photon emission tomography
26. Effects of canine myocardial infarction on sympathetic efferent neuronal function: Scintigraphic and electrophysiologic correlates
27. Acute and chronic effects of transient myocardial ischemia on sympathetic nerve activity, density, and norepinephrine content
28. 131I]metaiodobenzylguanidine after ischemia and reperfusion in anesthetized dogs
29. 123I]-MIBG) in patients with myocardial infarct
30. Regional sympathetic denervation after myocardial infarction in humans detected noninvasively using I-123-metaiodobenzylguanidine
31. Regional cardiac adrenergic function using I-123 meta-iodobenzylguanidine tomographic imaging after acute myocardial infarction
32. Evidence of functional alterations in sympathetic activity after myocardial infarction
33. Extent of cardiac autonomic denervation in relation to angina on exercise test in patients with recent acute myocardial infarction
34. I-123 metaiodobenzylguanidine-thallium-201 mismatch following myocardial infarction
35. Regional sympathetic denervation detected by iodine 123 metaiodobenzylguanidine in non-Q-wave myocardial infarction and unstable angina
36. 123I-labelled methyl-branched fatty acid and sympathetic imaging in acute coronary syndrome
37. Myocardial sympathetic nervous dysfunction detected with iodine-123-MIBG is associated with low heart rate variability after myocardial infarction
38. 123I] MIBG
39. 123I-MIBG
40. Sympathetic reinnervation after myocardial infarction
41. 123I-MIBG after acute myocardial infarction and reperfusion therapy
42. Influence of exercise rehabilitation on myocardial perfusion and sympathetic heart innervation in ischaemic heart disease
43. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes
44. Cardiac adrenergic denervation in patients with non-Q-wave versus Q-wave myocardial infarction
45. Cardiac adrenergic innervation within the first 3 months after acute myocardial infarction
46. Results of sympathetic denervation in the canine heart: Supersensitivity that may be arrhythmogenic
47. Detection of angina-provoking coronary stenosis by resting iodine 123 metaiodobenzylguanidine scintigraphy in patients with unstable angina pectoris
48. Regional myocardial sympathetic dysinnervation in patients with coronary vasospasm
49. Sympathetic nerve activity in the spasm-induced coronary artery region is associated with disease activity of vasospastic angina
50. Long-lasting abnormalities in cardiac sympathetic nervous system in patients with coronary spastic angina: Quantitative analysis with iodine 123 metaiodobenzylguanidine myocardial scintigraphy
51. 123I-MIBG myocardial scintigraphy as a non-invasive screen for the diagnosis of coronary artery spasm
52. The role of fatty acids in cardiac imaging
53. Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications
54. Diabetic autonomic neuropathy and cardiovascular risk
55. Cardiac autonomic neuropathy and QT interval length. A follow-up study in diabetic patients
56. The natural history of diabetic autonomic neuropathy
57. Mortality in diabetic patients with cardiovascular autonomic neuropathy
58. Occurrence, predictors, and clinical significance of autonomic neuropathy in NIDDM
59. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes
60. Evaluation of cardiac sympathetic neuronal integrity in diabetic patients using iodine-123 metaiodobenzylguanidine
61. 123I]metaiodobenzylguanidine
62. 123I]iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM. Comparison with cardiovascular reflex tests and relationship to left ventricular function
63. 123I-MIBG myocardial scintigraphy and power spectral analysis of heart rate variability
64. Scintigraphic evidence for cardiac sympathetic dysinnervation in long-term IDDM patients with and without ECG-based autonomic neuropathy
65. Association between QT dispersion and autonomic dysfunction in patients with diabetes mellitus
66. 123I-metaiodobenzylguanidine uptake in newly diagnosed IDDM patients
67. Autoantibodies against sympathetic ganglia and evidence of cardiac sympathetic dysinnervation in newly diagnosed and long-term IDDM patients
68. Partial restoration of scintigraphically assessed cardiac sympathetic denervation in newly diagnosed patients with insulin-dependent (type 1) diabetes mellitus at one-year follow-up
69. Increased QT dispersion and cardiac adrenergic dysinnervation in diabetic patients with autonomic neuropathy
70. Demonstration of regional sympathetic denervation of the heart in diabetes. Comparison between patients with NIDDM and IDDM
71. Relation of direct assessment of cardiac autonomic function with metaiodobenzylguanidine imaging to heart rate variability in diabetes mellitus
72. Three-year follow-up on scintigraphically assessed cardiac sympathetic denervation in patients with long-term insulin-dependent (type I) diabetes mellitus
73. Scintigraphically assessed cardiac sympathetic dysinnervation in poorly controlled type 1 diabetes mellitus: One-year follow-up with improved metabolic control
74. Left ventricular function and dimensions in newly diagnosed non-insulin-dependent diabetes mellitus
75. Abnormal cardiac function in diabetic patients with autonomic neuropathy in the absence of ischemic heart disease
76. Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus
77. Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients
78. Prevalence of QT prolongation in a type I diabetic population and its association with autonomic neuropathy
79. Sudden cardiac death-support for a role of triggering in causation
80. Sudden death and silent myocardial ischemia
81. Prolonged QT period in diabetic autonomic neuropathy: A possible role in sudden cardiac death?
82. QT Interval prolongation and sudden cardiac death in diabetic autonomic neuropathy
83. QT interval length and diabetic autonomic neuropathy
84. Silent ischemia in diabetic men with autonomic neuropathy
85. Silent myocardial infarction and diabetic autonomic neuropathy
86. Analysis of ambulatory electrocardiograms in 14 patients who experienced sudden cardiac death during monitoring
87. No difference in cardiac innervation of diabetic patients with painful and asymptomatic coronary artery disease
88. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function
89. Alteration of coronary perfusion reserve in hypertensive patients with diabetes
90. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus
91. Retinopathy identifies marked restriction of coronary flow reserve in patients with diabetes mellitus
92. Myocardial blood flow and glucose metabolism in diabetes mellitus
93. Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus
94. Coronary flow reserve is reduced in young men with IDDM
95. Scintigraphic assessment of regionalized defects in myocardial sympathetic innervation and blood flow regulation in diabetic patients with autonomic neuropathy
96. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus
97. Evidence for reduction of norepinephrine uptake sites in the failing human heart
98. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts
99. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms
100. Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy
101. Altered expression of beta-adrenergic receptor kinase and beta-1-adrenergic receptors in the failing human heart
102. Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration
103. Adverse consequences of high sympathetic nervous activity in the failing human heart
104. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure
105. Attenuated cardiac sympathetic responsiveness during dynamic exercise in patients with heart failure
106. Norepinephrine spillover to plasma in patients with congestive heart failure: Evidence of increased overall and cardiorenal sympathetic nervous activity
107. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy
108. Iodine-123 meta-iodobenzylguanidine scintigraphy: A noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy
109. Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants
110. Myocardial beta-adrenergic desensitization and neuronal norepinephrine uptake function in idiopathic dilated cardiomyopathy
111. Serial change of iodine-123 metaiodobenzylguanidine (MIBG) myocardial concentration in patients with dilated cardiomyopathy
112. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause
113. 201T1 in congestive heart failure
114. Relation of iodine-123 metaiodobenzylguanidine myocardial scintigraphy to endomyocardial biopsy findings in patients with dilated cardiomyopathy
115. Cardiac sympathetic activity as measured by myocardial 123-I-metaiodobenzylguanidine uptake and heart rate variability in idiopathic dilated cardiomyopathy
116. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy
117. 123I-MIBG scintigraphic study
118. Long-term course and cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy
119. 123I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy
120. Whole-body distribution of iodine 123 metaiodobenzylguanidine in hypertrophic cardiomyopathy: Significance of its washout from the heart
121. Scintigraphic assessment of cardiac adrenergic innervation in patients with essential hypertension
122. A method of dynamic analysis of iodine-123-metaiodobenzylguanidine scintigrams in cardiac mechanical overload hypertrophy and failure
123. Myocardial adrenergic nervous activity is intensified in patients with heart failure without left ventricular volume or pressure overload
124. Predictors of total mortality and sudden death in mild to moderate heart failure
125. Comparison between NYHA classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or dilated cardiomyopathy
126. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy
127. Correlates and prognostic implication of exercise capacity in chronic congestive heart failure
128. Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation
129. Factors influencing the one-year mortality of dilated cardiomyopathy
130. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure
131. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts
132. Beta-blockers in congestive heart failure: A Bayesian meta-analysis
133. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy
134. Use of iodine-123 metaiodobenzylguanidine myocardial imaging to predict the effectiveness of beta-blocker therapy in patients with dilated cardiomyopathy
135. 123I meta-iodobenzylguanidine imaging in predicting the effectiveness of beta blockers for patients with idiopathic dilated cardiomyopathy before and soon after treatment
136. 123I-MIBG in the failing human heart
137. 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy
138. 123I-MIBG scintigraphic study
139. Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity
140. Long-term effects of the angiotensin-converting enzyme inhibitor enalapril on chronic heart failure
141. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure
142. 123I]-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure
143. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease
144. Doxorubicin-induced cardiac neurotoxicity: Study with iodine 123-labeled metaiodobenzylguanidine scintigraphy
145. 123I] metaiodobenzylguanidine scintigraphy
146. Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity
147. Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts-implications for clinical studies
148. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of the transplanted human heart: Evidence for late reinnervation
149. Sympathetic re-innervation after heart transplantation: Dual-isotope neurotransmitter scintigraphy, norepinephrine content and histological examination
150. 123I-MIBG imaging
151. Effects of cardiac sympathetic innervation on coronary blood flow
152. Evidence for structural sympathetic reinnervation after orthotopic cardiac transplantation in humans
153. Normalization of sympathetic nervous system function after orthotopic cardiac transplant in man
154. Reinnervation of the transplanted human heart as evidenced from heart rate variability studies
155. Regional differences in sympathetic reinnervation after human orthotopic cardiac transplantation
156. Chest pain in cardiac transplant recipients
157. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias
158. Sudden cardiac death. Nonpharmacologic interventions
159. Time course of denervation of efferent sympathetic an vagal nerves after occlusion of the coronary artery in the canine heart
160. 123I-MIBG uptake in idiopathic ventricular tachycardia and fibrillation
161. Idiopathic ventricular tachycardia and fibrillation
162. Idiopathic ventricular fibrillation
163. 99mTc-MIBI and late ventricular potentials in patients after myocardial infarction: Association with the development of ventricular arrhythmias
164. Sympathetic innervation of the left ventricle is impaired in arrhythmogenic right ventricular disease
165. 123I-metaiodobenzylguanidine scintigraphy in the detection of irregular regional sympathetic innervation in long QT syndrome
166. Effects of cardiac sympathetic innervation on regional wall motion abnormality in patients with long QT syndrome
167. 123I] metaiodobenzyl-guanidine scans in patients with ventricular tachycardia and a "clinically normal" heart
168. Iodine-123-metaiodobenzylguanidine myocardial imaging in patients with right ventricular pressure overload
169. Myocardial uptake of metaiodobenzylguanidine in patients with left ventricular hypertrophy secondary to aortic stenosis
170. 123I]MIBG to assess cardiac adrenergic innervation: Experience in hypertensive cardiopathy and left ventricular aneurysms
171. 123I]iodobenzylguanidine in Parkinson's disease with autonomic failure
172. Differentiation of Parkinson's disease and the multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT
173. Cardiac sympathetic denervation from the early stage of Parkinson's disease: Clinical and experimental with radiolabeled MIBG
174. (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease
175. 123I-MIBG uptake in Parkinson's disease
176. 123I-MIBG uptake by the heart in Parkinson's disease: Assessment of cardiac sympathetic denervation and diagnostic value
177. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific
178. Scintigraphic differentiation between two forms of primary dysautonomia early after onset of autonomic dysfunction: Value of cardiac and pulmonary iodine-123 MIBG uptake
179. Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability
180. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients in with familial amyloid polyneuropathy